Home › Acute Lymphoblastic Leukemia › Illinois
Pag-aaral pangklinika para sa Acute Lymphoblastic Leukemia sa Illinois
20 pag-aaral para sa Acute Lymphoblastic Leukemia ang naghahanap ng mga kalahok sa mga site sa Illinois.
Mga Lungsod sa Illinois
Opisyal na teksto ng pag-aaral (English)
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- OSF Saint Anthony's Health Center, Alton
- Rush-Copley Medical Center, Aurora
- Advocate Outpatient Center - Aurora, Aurora
- at 54 pa
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 40 hanggang 75 · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT05334069A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- The University of Chicago Medical Center, Chicago
Nagre-recruitPhase 1/2
30 Days · Lahat ng kasarian · Na-update Set 16, 2026 · NCT04065399The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Lurie Children's Hospital-Chicago, Chicago
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- at 6 pa
Nagre-recruitPhase 1/2
Hanggang edad 22 · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT04726241Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Nagre-recruitPhase 2
Edad 7 hanggang 25 · Lahat ng kasarian · Na-update Ago 19, 2026 · NCT05082519A Study of CTD402 in T-ALL/LBL Patients
- University of Chicago, Chicago
Nagre-recruitPhase 1/2
Edad 1 pataas · Lahat ng kasarian · Na-update Ago 19, 2026 · NCT07070219Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment
- The University of Chicago, Chicago
Nagre-recruitObservasyonal na pag-aaral
1 Day – 17 Years · Lahat ng kasarian · Na-update Ago 14, 2026 · NCT06274788Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
- Research Site, Decatur
Nagre-recruitPhase 1/2
Edad 16 pataas · Lahat ng kasarian · Na-update Hul 20, 2026 · NCT07155226Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
- Research Site, Chicago
Nagre-recruitPhase 1/2
Edad 12 pataas · Lahat ng kasarian · Na-update Hul 13, 2026 · NCT07109219Using Text Messages to Improve Oral Chemotherapy for Adolescents and Adults With Acute Lymphoblastic Leukemia
- University of Chicago Medicine Comprehensive Cancer Center, Chicago
Nagre-recruit
Edad 15 pataas · Lahat ng kasarian · Na-update Hul 10, 2026 · NCT06446661A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Northwestern Memorial Hospital, Chicago
- Rush University Medical Center, Chicago
- University of Illinois at Chicago, Chicago
- at 3 pa
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update Hul 6, 2026 · NCT01351545Mobile Health Intervention to Support Oral Chemotherapy Adherence in Adolescents and Young Adults With Leukemia
- Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago
Nagre-recruit
Edad 14 pataas · Lahat ng kasarian · Na-update Hun 30, 2026 · NCT03932903Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia
- University of Chicago Medical Center, Chicago
Nagre-recruitPhase 1
Edad 18 hanggang 39 · Lahat ng kasarian · Na-update Hun 29, 2026 · NCT03571321Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)
- University of Chicago Medical Center, Chicago
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 5, 2026 · NCT04747912Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- Lurie Children's Hospital-Chicago, Chicago
- Advocate Children's Hospital-Oak Lawn, Oak Lawn
- Saint Jude Midwest Affiliate, Peoria
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update May 18, 2026 · NCT01790152Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- University of Chicago, Chicago
Nagre-recruitPhase 1
Edad 13 pataas · Lahat ng kasarian · Na-update May 5, 2026 · NCT04771572A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Northwestern, Chicago
Nagre-recruitPhase 1/2
Edad 12 pataas · Lahat ng kasarian · Na-update Mar 24, 2026 · NCT04988555A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)
- University of Chicago Medicine Comprehensive Cancer Center, Chicago
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 18, 2026 · NCT06207123Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- University of Chicago Comprehensive Cancer Center, Chicago
Nagre-recruitPhase 2
Edad 18 hanggang 54 · Lahat ng kasarian · Na-update Mar 17, 2026 · NCT06918431Venetoclax Basket Trial for High Risk Hematologic Malignancies
- Ann & Robert H Lurie Children's Hospital of Chicago, Chicago
Nagre-recruitPhase 1
Edad 1 hanggang 40 · Lahat ng kasarian · Na-update Mar 12, 2026 · NCT05292664Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Nagre-recruitPhase 1
Edad 1 hanggang 21 · Lahat ng kasarian · Na-update Dis 6, 2024 · NCT05476770Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.